ArticleInfluenza and other respiratory viruses2019
Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: A 6-year retrospective study.
Article in Influenza and other respiratory viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Burden of respiratory syncytial virus in adults in the United Kingdom: A systematic literature review and gap analysis.Influenza and other respiratory viruses · 2023Pooled it
- Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis.Epidemiology and infection · 2020Pooled it
- Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine.The Journal of infectious diseases · 2023Trial
- Respiratory syncytial virus in adults aged ≥ 50 years in France: a database and time-series modelling analysis (2014-2020).Infection · 2026Observational
- Exploring the Link Between RSV Infection and Antibiotic Prescriptions in Older Adults: A Systematic Review.Antibiotics (Basel, Switzerland) · 2026Review
- Intensive Care Unit Stay and Mechanical Ventilation Among Adults with Respiratory Syncytial Virus-Related Hospitalization by Age and Comorbidity Status.Infectious diseases and therapy · 2026Article
- Seasonal variation in respiratory syncytial virus-specific IgG concentrations in Northern Plains American Indian children with asthma.The journal of allergy and clinical immunology. Global · 2025Article
- Integrated Metabolomics and Network Pharmacology to Reveal the Mechanisms ofInternational journal of molecular sciences · 2025Article
- Epidemiological and Clinical Characteristics of Adult RSV Infections: A Retrospective Analysis at University Hospital Center Zagreb (2022-2024).Pathogens (Basel, Switzerland) · 2025Article
- Pathogen spectrum and management strategies for opportunistic infections in lung cancer in the immunotherapy era: recent advances from fungi to mycobacteria.American journal of cancer research · 2025Review
- Severe respiratory syncytial virus disease.Journal of intensive medicine · 2024Review
- Adult Respiratory Syncytial Virus Infection: Defining Incidence, Risk Factors for Hospitalization, and Poor Outcomes, a Regional Cohort Study, 2016-2022.Pathogens (Basel, Switzerland) · 2024Article
- Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Review
- Epidemiology and Disease Burden of Respiratory Syncytial Virus Infection in Adults.Infection & chemotherapy · 2024Review
- Prevalence and Clinical Outcomes of Respiratory Syncytial Virus vs Influenza in Adults Hospitalized With Acute Respiratory Illness From a Prospective Multicenter Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Epidemiology and Characteristics of Respiratory Syncytial Virus Pneumonia in Critically Ill Adults.Open forum infectious diseases · 2023Article
- Diabetes and bacterial co-infection are two independent risk factors for respiratory syncytial virus disease severity.Frontiers in medicine · 2023Article
- Characterization of an orally available respiratory syncytial virus L protein polymerase inhibitor DZ7487.American journal of translational research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRespiratory syncytial virus (RSV) is an important cause of morbidity and mortality in adults. Existing studies are limited by the number of seasons studied and most have focused on the immunocompromised.
methodsA retrospective cohort study was conducted on all adults (≥18 years) with a positive RSV molecular test admitted from 2009 to 2015 to one hospital in Chicago, IL. Epidemiologic and outcomes data were collected after IRB approval.
resultsOf the 489 eligible patients, 227 had RSV A and 262 had RSV B. Patients had a median age of 61 years and comorbidity (eg, chronic lung disease [40.6%], obesity [37.8%], and cardiac disease [34.3%]). On presentation, most had cough (86.5%), fever (42.4%), and shortness of breath (38.2%). Severe disease was present in 27.6% of patients. Antibiotic was used in 76.3% inpatients and 45.8% at discharged despite few patients (4.7%) having documented bacterial infections. Supplemental oxygen and mechanical ventilation were utilized in 44.6% and 12.3%, respectively, while ICU level care was required in 26.9%. Most patients were discharged home (82.7%). Most deaths (68.4%, 13/19) were attributed to pneumonia or hypoxemia likely from RSV. Most fatal cases were seen in those with recent cancer treatment and older adults.
conclusionsRespiratory syncytial virus in hospitalized adults is associated with significant morbidity and mortality with 26.9% requiring ICU level care. Antibiotics are commonly prescribed to patients with documented RSV, and antibiotics are frequently continued after diagnosis. Novel antiviral therapies are needed for RSV to improve outcomes and potentially improve antibiotic stewardship in patients without a bacterial infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.